Research programme: small molecule therapeutics - Ono Pharmaceuticals/PRISM BioLab/
Latest Information Update: 21 May 2024
At a glance
- Originator PRISM BioLab
- Developer Ono Pharmaceutical; PRISM BioLab
- Class Antineoplastics; Peptidomimetics; Small molecules
- Mechanism of Action Protein-protein interaction inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Cancer